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Abstract
Background: ML 3000 ([2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-
yl]-acetic acid) is an inhibitor of both cyclooxygenase and 5-lipoxygenase in vitro, and shows
promise as a novel non-steroidal anti-inflammatory drug (NSAID). Unlike conventional NSAIDs
which are associated with gastric ulcerogenic effects, ML 3000 causes little or no damage to the
gastric mucosa, even though it significantly depresses gastric prostaglandin synthesis.
Methods: As part of an effort to clarify mechanisms underlying the gastric sparing properties of
ML 3000, we studied the effects of ML 3000 on H,K-ATPase activity in vitro, on acid accumulation
in isolated gastric parietal cells, and on IL-8 secretion by gastric epithelial cells in culture.
Results: SCH28080-sensitive H,K-ATPase activity in highly-purified pig gastric microsomes was
dose-dependently inhibited by ML 3000 (IC50 = 16.4 µM). Inhibition was reversible, and insensitive
to ML 3000 acidification in the pH range 2.0–8.0. In rabbit gastric parietal cells,
ML 3000 dose-dependently inhibited histamine-stimulated acid accumulation (IC50 = 40 µM) and
forskolin-stimulated acid accumulation (IC50 = 45 µM). Lastly, in human gastric adenocarcinoma
(AGS) cells, ML 3000 dose-dependently inhibited both baseline and IL-1β-stimulated (20 ng/ml) IL-
8 secretion with IC50s of 0.46 µM and 1.1 µM respectively.
Conclusion: The data indicate that ML 3000 affects acid-secretory mechanisms downstream of
cAMP mobilization induced by histamine H2 receptor activation, that it directly inhibits H,K-ATPase
specific activity, and that baseline gastric epithelial cell IL-8 secretory inhibition may be mediated by
ML 3000 inhibition of 5-lipoxygenase activity. We conclude that these gastric function inhibitory
data may underlie the gastric sparing properties of ML 3000.
Background
The pharmacological properties of nonsteroidal anti-
inflammatory drugs (NSAIDs) arise from their suppres-
sion of prostaglandin synthesis from arachidonic acid [1].
Inhibition of gastric prostaglandin syntheses is accompa-
nied however by decreased gastric mucosal blood flow,
with concomitant mucosal sensitivity to topical injury by
a variety of irritants [2]. A promising pharmacological
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strategy to avoid gastric complications of NSAID adminis-
tration focuses on concurrent cyclooxygenase and 5-lipox-
ygenase inhibition, with the objective of suppressing
leukotriene synthesis. 5-lipoxygenase converts arachi-
donic acid to leukotrienes, among which leukotriene B4 is
chemotactic for leukocytes and thereby contributes to
inflammatory mechanisms leading to gastrointestinal
ulcers [3]. The pyrrolizine derivative ML 3000 ([2,2-dime-
thyl-6-(4-chlorophen-yl)-7-phenyl-2,3-dihydro-1H-pyr-
rolizine-5-yl]-acetic acid) is an inhibitor of both cyclo-
oxygenase and 5-lipoxygenase in vitro [4,5], and shows
promise as a novel NSAID. ML 3000 reduces gastric pros-
taglandin E2 synthesis in rat stomach and blood,
although significant inhibition of gastric or blood leukot-
riene B4 synthesis was not detected [6]. Most importantly,
ML 3000 has no effect on leukocyte adherence in
mesenteric venules, and causes no gastric mucosal injury
[6].
In animal models, ML 3000 was found to be pharmaco-
logically benign. Thus, the compound did not affect rat
locomotor activity or hexobarbital-induced sleep, had no
cardiovascular or respiratory effects in rat and dogs, was
without affect on neuromuscular function in cats, and
caused neither gastric damage nor peristaltic disturbance
[7]. ML 3000 evoked a weak spasmogenic response in
guinea-pig ileum, and caused a small transient reduction
in urine output in rats [7]. Genotoxicity studies indicate
that ML 3000 has no effects on gene mutation frequencies
in bacteria or mammalian cells, on unscheduled DNA
synthesis, or on frequency of chromosomal aberrations in
rat bone marrow cells [8]. 14C-labeled ML 3000 distribu-
tion and excretory studies in rats indicate enterohepatic
circulation and glucuronide conjugation of ML 3000 [9].
The pharmacological profile of ML 3000 as studied in ani-
mal models shows anti-inflammatory, analgesic, antipy-
retic, antiasthmatic, and antiaggregative activity at a
dosage that causes no gastric damage [4,10]. The acute
and chronic anti-inflammatory properties of ML 3000
studied in the adjuvant-induced rat paw edema model
[11] show that although indomethacin is somewhat more
potent as an anti-inflammatory agent, no gastric damage
was noted with ML 3000 up to 100 mg/kg/d p.o., whereas
the ulcerogenic dose (UD50) for indomethacin was 7 mg/
kg/d p.o.
Gastric ulceration induced by NSAIDs significantly limits
the utility of these drugs. Clearly, the combination of anti-
inflammatory and gastric sparing properties exhibited by
ML 3000 makes this compound an attractive candidate for
further study. Two gastric mucosal functions which play
important roles in gastric ulceration are acid secretion and
interleukin-8 secretion. Acid secretory inhibitors are
among the most highly-prescribed medications, reflecting
the physiological adage "No acid, no ulcer". Pharmaco-
logical or pathophysiological breaching of the gastric
mucosal barriers to back diffusion of HCl leads to rapid
erosion of the gastric epithelial monolayer and conse-
quent ulceration of the mucosa. Inhibition of acid secre-
tion by antagonism at the parietal cell histamine H2
receptor (cimetidine), or by direct covalent derivatization
and inactivation of the gastric proton pump (omeprazole,
lansoprazole, rabeprazole, esomeprazole, etc) is routine
for amelioration and promotion of healing of gastric
ulcers. Thus, the gastric sparing effects of ML 3000 may be
related to acid secretory inhibition by the compound.
A complementary gastric sparing effect of ML 3000 may
involve modulation of gastric secretion of the pro-inflam-
matory cytokine IL-8. Aspirin-induced gastric injury has
been reported to be associated with increased antral pro-
duction of IL-8 [12]. The ulcerogenic bacterium Helico-
bacter pylori has been shown to increase the rate and
amplitude of IL-8 secretion both in vitro and in vivo [13-
15], and to up-regulate IL-8 gene expression [16]. Similar
IL-8 prosecretory effects are seen as a result of IL-1β stim-
ulation of gastric epithelial cells. Comparison of the
effects of ML 3000 and of other NSAIDs on these gastric
secretory activities may elucidate the mechanism by
which ML 3000 prevents the formation of gastric mucosal
lesions.
In order to clarify mechanisms underlying the gastric spar-
ing properties of ML 3000, we investigated the effect of
ML 3000 on two gastric mucosal secretory functions with
roles in ulcerogenesis: secretion of hydrochloric acid, and
secretion of the inflammatory cytokine interleukin-8. Our
data show that ML 3000 inhibits pig gastric microsomal
H,K-ATPase activity, inhibits histamine-stimulated acidi-
fication in rabbit gastric parietal cells, and inhibits IL-1β-
stimulated IL-8 secretion by human gastric epithelial cells.
Methods
Reagents
ML 3000 and ZD-2138 were provided by Forest Laborato-
ries, Inc., New York, NY, omeprazole was provided by
AstraZeneca R & D, Molndal, Sweden, SCH 28080 was
from Schering-Plough Research Institute, Kenilworth, NJ,
TEDBC came from Tocris Cookson, Inc., Ballwin, MO,
and NS 398 came from Cayman Chemicals, Inc., Ann
Arbor, MI. Arachidonic acid, indomethacin, acetyl sali-
cylic acid, naproxen, PGE2, leukotrienes B4 and D4, and
IL-1β were all acquired from Sigma-Aldrich Corp., St.
Louis, MO. Dimethyl sulfoxide (Sigma-Aldrich) was used
to solubilize ML3000, SCH28080, ZD-2138, TEDBC, NS
398, and indomethacin. Acetyl salicylic acid and
naproxen were dissolved in ATPase assay buffer (vide
infra). Arachidonic acid and PGE2 were dissolved in abso-
lute ethanol, and omeprazole was dissolved in methanol.BMC Gastroenterology 2004, 4 http://www.biomedcentral.com/1471-230X/4/4
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Leukotrienes B4 and D4 were supplied dissolved in a
70:30 mix of methanol and 17 mM ammonium acetate.
IL-1β was dissolved in phosphate-buffered saline (pH
7.4), 0.1% w/v bovine serum albumin. All assays using
these compounds included appropriate solvent controls,
and all solvents were present at concentrations less than
1% w/v in the final assay mixture.
Preparation of H,K-ATPase
Microsomal gastric H,K-ATPase was prepared from pig
gastric mucosal homogenates by differential and sucrose/
Ficoll step gradient centrifugation as described previously
[17]. This preparation yields a relatively heavy (7% Ficoll/
1.1 M sucrose interface) GII microsomal fraction, which
showed no latency of K-ATPase activity, and which com-
prised ~90% H,K-ATPase, based on densitometry of a 94
kDa band by SDS-PAGE analysis. GII microsomes were
stored at -80°C in 20% glycerol.
H,K-ATPase Assay
ATP hydrolytic activity of pig gastric microsomes was
quantitated as orthophosphate release from substrate ATP
using a colorimetric malachite green procedure [18].
ATPase assays were carried out in 96-well microplates.
Briefly, 100 µl/well assay buffer (60 mM Tris-HCl, pH 7.4,
2 mM MgCl2, 1 mM EGTA, ± 7.5 mM KCl, ± 50 µM
SCH28080), containing 80 ng microsomal H,K-ATPase,
ML 3000 (10-9 M to 10-4 M) or other compounds, and 1
mM ATP was incubated for 30 min at 37°C. Enzymatic
activity was stopped by addition (45 µl/well) of colori-
metric reagent (0.07% malachite green, 3.7 NH2SO4,
2.27% ammonium molybdate tetrahydrate, 0.134%
Tween-20). After 10 seconds, the color reaction was devel-
oped by addition (45 µl/well) of 15% sodium citrate.
After 45 min at room temperature, absorbance of the
wells at 570 nm was measured in a microplate reader.
To measure the effects of ML 3000 acidification on ATPase
inhibition, ML 3000 aliquots (10 mM in 5 mM Tris-HCl)
were titrated to pHs ranging from 2.0 to 7.4 for 30 min.
Gastric microsomes suspended in standard ATPase assay
buffer at pH 7.4 were incubated for 30 min with acidified
aliquots of ML 3000 (16.6 µM final ML 3000 concentra-
tion) and then ATPase activity was measured as described
above. To measure omeprazole inhibition of H,K-ATPase
activity, gastric microsomes suspended in ATPase assay
buffer at pH 6.1 were incubated for 30 min with varying
concentrations of omeprazole. Omeprazole acidification
to pH 6.1 was necessary to allow formation of the inhibi-
tory thiol-reactive sulfoxide intermediate [19]. The gastric
microsomes were then transferred to standard ATPase
assay buffer at pH 7.4, and ATPase activity was measured
as described above. Specific H,K-ATPase activity was cal-
culated as the difference in microsomal ATPase activities
in the presence and absence of the specific reversible gas-
tric H,K-ATPase inhibitor SCH28080, and was expressed
as  µmoles Pi/mg protein/hr. H,K-ATPase activity of
freshly-prepared pig gastric microsomes ranged from 140
to 170 µmoles Pi/mg protein/hr. Graphical depiction of
the data shows percent inhibition of H,K-ATPase activity
as a function of compound concentrations.
Primary Cell Preparation
Gastric parietal cells were isolated from New Zealand
White rabbits by pronase/collagenase digestion of fundic
mucosa followed by enrichment of cells on discontinuous
Nycodenz gradients as described previously [20]. Parietal
cell preparations contained approximately 107 cells/stom-
ach, of which 80 ± 5% were parietal cells based on immu-
nocytochemistry with H,K-ATPase-specific monoclonal
antibody.
Acid Accumulation Assay
Aminopyrine accumulation into parietal cells was
assessed in 96 well filter plates with Durapore mem-
branes, as described previously [21]. Briefly, cells were
preincubated with [14C]-aminopyrine and then 100,000
cells/200 µl per well were incubated without or with test
compounds for 15 minutes prior to incubation for a fur-
ther 30 min in the absence or presence of 100 µM hista-
mine or 100 µM forskolin. All determinations were
performed in quadruplicate. Basal aminopyrine accumu-
lation was determined as aminopyrine accumulation into
untreated cells subtracted from accumulation in the pres-
ence of KSCN (a reflection of non-specific isotope trap-
ping). Graphical depiction of the data shows percent
inhibition of histamine-stimulated acid accumulation by
the cells as a function of compound concentrations.
Gastric Adenocarcinoma Cells
Human gastric adenocarcinoma cells (AGS cells, ATCC
CRL 1739), were maintained in AGS medium (Ham's F-
12, 10% fetal bovine serum, 100 units/ml penicillin G,
0.25 ug/ml amphotericin B, 100 ug/ml streptomycin) at
37°C in a 5% CO2/95% air incubator and used between
passages 42 and 56. For studies of IL-8 secretion, AGS cells
were plated into 96-well plates (50,000 cells/100 µl/well)
and allowed to attach for 18 hr at 37°C in 5% CO2/95%
air. Cells were then incubated with test compounds in the
presence and absence of IL-1β for 24 hr, at which time
samples of medium were removed from the wells and
stored at -70°C. IL-8 concentrations of the samples were
determined by enzyme-linked immunosorbent assay
(Human IL-8 Duo-Set ELISA development system, R&D
Systems Inc., Minneapolis, MN). Graphical depiction of
the data shows percent inhibition of unstimulated or
stimulated IL-8 secretion as a function of compound
concentrations.BMC Gastroenterology 2004, 4 http://www.biomedcentral.com/1471-230X/4/4
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Statistical Analysis
All experiments were carried out at least three times; data
points in each assay represent measurement means from
triplicate samples. Data points fitting a three parameter
logistic equation were graphed as sigmoidal dose-
response curves using the Prism statistical package
(GraphPad Software, Inc., San Diego, CA). Half-maximal
inhibitory concentrations (IC50) and IC50 95% confidence
intervals (CI) were also calculated using Prism. Data
points not fitting a three parameter logistic were drawn as
simple point-to-point curves. Standard error was the
measure of variance used for error bars in graphical depic-
tion of data
Results
Effects of ML 3000 on H,K-ATPase activity
Gastric H,K-ATPase activity was dose-dependently inhib-
ited by ML 3000, with a half-maximal inhibitory concen-
tration (IC50) of 16.4 µM (CI = 6.84 – 39.3 µM) (Figure
1A). The inhibitory activity of ML 3000 was compared to
that of a classical proton pump inhibitor (PPI), the substi-
tuted benzimidazole omeprazole. Figure 1B shows the
effect of omeprazole on H,K-ATPase activity under assay
conditions identical to those in Figure 1A; the calculated
IC50 for omeprazole was 1.7 µM (CI = 0.26 – 11.3 µM).
These data show that ML 3000 is considerably less potent
than omeprazole with respect to gastric H,K-ATPase
inhibitory activity, at least in the setting of this particular
in vitro assay under the specified conditions. To deter-
mine whether ML 3000 displayed comparable acid-activa-
tion properties, a half-maximal inhibitory concentration
of ML 3000 was titrated to different pHs and the effects on
H,K-ATPase activity were measured. As shown in Figure
2A, acidification of ML 3000 had no significant effect on
its H,K-ATPase inhibitory profile. These data indicate that
ML 3000, in contrast to omeprazole, does not require
acidification for induction of inhibitory activity. Given
that PPIs are irreversible inhibitors of H,K-ATPase activity,
covalently binding to the catalytic α subunit, we sought to
determine whether ML 3000 inhibition of H,K-ATPase
was reversible or irreversible. Gastric H,K-ATPase-
enriched microsomes were treated with a maximally-
inhibitory concentration of ML 3000 and then diluted
with a large excess of buffer to reduce the ML 3000 con-
centration from 100 µM to 3.3 µM. The results, shown in
Figure 2B, indicated that dilution of ML 3000 restored
H,K-ATPase activity, and are consistent with ML 3000
inhibiting H,K-ATPase activity in a reversible manner, ie.,
ML 3000 does not covalently derivatize either subunit of
the gastric H,K-ATPase, at least under the conditions of the
present in vitro assay of H,K-ATPase activity. In this
respect, ML 3000 is kinetically similar to SCH28080, the
specific reversible inhibitor of gastric H,K-ATPase.
Arachidonic acid and prostaglandin E2 (PGE2) also dose-
dependently inhibited H,K-ATPase activity, with IC50 of
16.7 µM (CI = 8.9 – 31.5 µM) and 15 µM (CI = 3.96 – 57.3
µM) respectively (Figure 3A and 3B). Since ML 3000 also
Dose-dependent inhibition of H,K-ATPase activity by ML  3000 (A) and by omeprazole (B) Figure 1
Dose-dependent inhibition of H,K-ATPase activity by 
ML 3000 (A) and by omeprazole (B). (A). Gastric 
microsomes suspended in ATPase assay buffer at pH 7.4 
were incubated for 30 min with varying concentrations of ML 
3000 and ATPase activity was then measured at pH 7.4. The 
half-maximal inhibitory concentration (IC50) for ML 3000 was 
16.4 µM (CI = 6.84–39.3 µM). (B). Gastric microsomes sus-
pended in ATPase assay buffer at pH 6.1 were incubated for 
30 min with varying concentrations of omeprazole, and then 
transfered to standard ATPase assay buffer at pH 7.4 for 
ATPase activity measurement. The IC50 for omeprazole was 
1.1 µM (CI = 0.26 – 11.3 µM). The data-points show mean ± 
s.e. from three independent assays in each of which 
SCH28080-sensitive ATPase activity was measured in 
triplicate.
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shows 5-lipoxygenase inhibition, we studied the effects of
two lipoxygenase inhibitors on microsomal H,K-ATPase
activity. Figure 4A shows that 2-(1-thienyl)ethyl 3,4-dihy-
droxybenzylidenecyanoacetate (TEDBC), a powerful
inhibitor of 5-, 12-, and 15-lipoxygenses, inhibited micro-
somal H,K-ATPase activity with an IC50 of 22.6 µM (CI =
6.3 – 81.2 µM). In contrast, the 5-lipoxygenase-specific
inhibitor 6-((3-fluor-5-(methoxy-3,4,5,6-tetrahydro-2H-
pyran-4-yl)phenoxy)methyl)chinolin (ZD-2138) had a
minimal effect on H,K-ATPase activity (~20% inhibition
at 10-5 M) (Figure 4B). These data are consistent with gas-
tric microsomal 12- and 15-lipoxygenases playing a role
in H,K-ATPase activation, or with direct interaction of
TEDBC with H,K-ATPase subunits altering enzyme con-
formation and hence activity. Clearly, both interpreta-
tions are provocative and merit further study.
Effect of ML 3000 acidification on H,K-ATPase activity (A),  and ML 3000 inhibition of H,K-ATPase activity is reversible  (B) Figure 2
Effect of ML 3000 acidification on H,K-ATPase activ-
ity (A), and ML 3000 inhibition of H,K-ATPase activ-
ity is reversible (B). (A) ML 3000 aliquots (10 mM in 5 mM 
Tris-HCl) were titrated to pHs ranging from 2.0 to 7.4 for 30 
min before addition to standard ATPase assay buffer (pH 7.4) 
containing gastric microsomes. (B) Gastric microsomes were 
treated with a maximally-inhibitory concentration (100 µM) 
of ML 3000. The microsomal suspension was then diluted 
with a large excess of buffer to reduce the ML 3000 concen-
tration from 100 µM to 3.3 µM. In both (A) and (B), the 
data-points show mean ± s.e. from three independent assays 
in each of which SCH28080-sensitive ATPase activity was 
measured in triplicate.
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Inhibition of H,K-ATPase activity by arachidonic acid (A) and  prostaglandin E2 (B) Figure 3
Inhibition of H,K-ATPase activity by arachidonic acid 
(A) and prostaglandin E2 (B). Gastric microsomes sus-
pended in ATPase assay buffer at pH 7.4 were incubated for 
30 min with varying concentrations of arachidonic acid or 
PGE2 and ATPase activity was then measured at pH 7.4. IC50 
for arachidonic acid was 16.7 µM (CI = 8.9 – 31.5 µM), and 
the IC50 for PGE2 was 15 µM (CI = 3.96 – 57.3 µM). The 
data-points show mean ± s.e. from three independent assays 
in each of which SCH28080-sensitive ATPase activity was 
measured in triplicate.
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In order to compare the H,K-ATPase inhibitory effect of
ML 3000 with other NSAIDS, we measured the effects of
acetyl salicylic acid, NS 398, naproxen, and indomethacin
on proton pump activity. All four NSAIDS were without
inhibitory effects on microsomal H,K-ATPase activity at
concentrations up to 10-4 M (10-3 M for acetyl salicylic
acid) (Figure 5A,5B,5C and 5D). Indomethacin was previ-
ously reported to inhibit gastric H,K-ATPase at somewhat
higher concentration (Ki = 0.67 × 10-3 M) [22]. Our data
clearly differentiate ML 3000 from other NSAIDS in terms
of inhibitory effect on gastric H,K-ATPase activity; the
mechanistic basis for this difference, and the potential
correlation with the observed gastric-sparing property of
ML 3000, remain to be investigated.
Lastly, in order to establish whether the ML 3000 inhibi-
tion of gastric H,K-ATPase reflected the compound's
effects on putative functional leukotriene metabolic path-
ways present in pig gastric microsomes, we studied the
effects of leukotriene B4 and D4 on H,K-ATPase activity.
Solubility issues precluded studying LTB4 or LTD4 con-
centrations greater than 1 µM. As shown in Figure 6A and
6B, neither leukotriene showed any inhibitory activity
against H,K-ATPase at physiological concentrations (10-9–
10-8 M); only at non-physiological concentrations greater
than 10-7 M was there any significant attenuation of H,K-
ATPase activity.
Effects of ML 3000 on gastric parietal cell histamine-
stimulated acid accumulation
ML 3000 dose-dependently inhibited histamine-stimu-
lated (100 µM) acid accumulation by rabbit gastric pari-
etal cells, with a half-maximal inhibitory concentration
(IC50) of 40 µM (Figure 7A). ML 3000 also dose-depend-
ently inhibited forskolin-stimulated (100 µM) acid accu-
mulation by rabbit gastric parietal cells, with an IC50 of
~45 µM (Figure 7B). These data indicate that ML 3000
affects parietal cell acid-secretory mechanisms down-
stream of cAMP mobilization induced by histamine H2
receptor activation. The data are consistent with ML 3000
inhibition of parietal cell acid secretion resulting from
direct interaction of ML 3000 with the gastric H,K-ATPase.
However, the discepancy between ML 3000 IC50 in micro-
somal vesicles (15 µM) and in isolated parietal cells (40–
45 µM) suggests that ML 3000 access to the intracellular
H,K-ATPase compartment in parietal cells may be slowed
by permeability constraints at the plasma membrane.
Alternatively, ML 3000 may be subject to cytoplasmic
metabolic modifications which limit inhibitory potency
of the compound.
Finally, as was found with microsomal H,K-ATPase, other
NSAIDS such as acetyl salicylic acid, naproxen, and NS
398 (up to concentrations of 10-4 M) had no effect on acid
accumulation by isolated rabbit parietal cells (data not
shown)
Effects of ML 3000 on IL-1β-induced IL-8 secretion in 
human gastric adenocarcinoma (AGS) cells
Under baseline conditions, AGS cells (5 × 104 in 100 µl
culture medium) secreted IL-8 over a period of 24 hr to a
concentration of ~225 pg/ml medium. When stimulated
by IL-1β (1 ng/ml), AGS cell IL-8 secretion over a period
of 24 hr was increased ~27-fold, to a concentration of
Inhibition of H,K-ATPase activity by the 5-, 12-, and 15-lipox- ygenase inhibitor TEDBC (A), and the 5-lipoxygenase inhibi- tor ZD-2138 (B) Figure 4
Inhibition of H,K-ATPase activity by the 5-, 12-, and 
15-lipoxygenase inhibitor TEDBC (A), and the 5-
lipoxygenase inhibitor ZD-2138 (B). Gastric micro-
somes suspended in ATPase assay buffer at pH 7.4 were 
incubated for 30 min with varying concentrations of TEDBC 
or ZD-2138 and ATPase activity was then measured at pH 
7.4. In (A), the data-points show mean SCH28080-sensitive 
ATPase activity measured in triplicate in one of three inde-
pendent assays; typical data are shown. The data-points in 
(B) show mean ± s.e. from three independent assays in each 
of which SCH28080-sensitive ATPase activity was measured 
in triplicate.
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~6000 pg/ml. ML 3000 inhibited both baseline and IL-1β-
stimulated IL-8 secretion, with IC50s of 0.46 µM (CI = 0.09
– 2.4 µM) and 1.1 µM (CI = 0.52 – 2.2 µM) respectively
(Figure 8A and 8B).
The 5-lipoxygenase-specific inhibitor (ZD-2138), which
was without effect on microsomal H,K-ATPase activity,
showed dose-responsive inhibition of baseline AGS cell
IL-8 secretion (Figure 8C), with an IC50 of 58 nM (CI =
15.6 – 218 nM). ZD-2138 showed minimal effect on IL-
1β-stimulated IL-8 secretion by AGS cells (Figure 8D).
H,K-ATPase inhibition by ML 3000, which we have dem-
onstrated in the present study, does not underlie IL-8
secretory inhibition in this model because immunocyto-
chemistry with H,K-ATPase-specific monoclonal antibody
Effects of acetyl salicylic acid, NS 398, naproxen, and indomethacin on H,K-ATPase activity Figure 5
Effects of acetyl salicylic acid, NS 398, naproxen, and indomethacin on H,K-ATPase activity. Gastric microsomes 
suspended in ATPase assay buffer at pH 7.4 were incubated for 30 min with varying concentrations of acetyl salicylic acid, NS 
398, naproxen, or indomethacin and ATPase activity was then measured at pH 7.4. The data-points show mean SCH28080-
sensitive ATPase activity measured in triplicate in one of three independent assays; typical data are shown in each case.
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shows no H,K-ATPase expression in AGS cells (data not
shown).
Discussion
This study provides information about the effects of ML
3000 on aspects of gastric physiology related to ulcerogen-
esis. Three experimental models of gastric function were
investigated; highly-purified functional H,K-ATPase (pro-
ton pump) isolated from the gastric mucosa of
slaughterhouse hogs, isolated rabbit gastric parietal cells,
and human gastric adenocarcinoma cells in culture. In the
first model, ML 3000 inhibited the proton pump with an
IC50 of 16.4 µM. The proton pump inhibitor (PPI) ome-
prazole displayed an IC50 of 1.1 µM in the same assay.
Unlike PPIs, ML 3000 inhibitory activity was independent
of pH and was reversible. Selective and non-selective
NSAIDS showed no H,K-ATPase inhibitory activity in the
same assay. In the second model, ML 3000 inhibited both
histamine and forskolin-stimulated acid accumulation
(IC50 = 40 and 45 µM), consistent with ML 3000 proton
pump inhibition. In the third model, ML 3000 inhibited
both baseline and IL-1β-stimulated interleukin-8 secre-
tion from AGS cells (IC50 = 0.46 and 1.1 µM respectively),
Effects of leukotrienes B4 and D4 on SCH28080-sensitive  H,K-ATPase specific activity Figure 6
Effects of leukotrienes B4 and D4 on SCH28080-sen-
sitive H,K-ATPase specific activity. Gastric microsomes 
suspended in ATPase assay buffer at pH 7.4 were incubated 
for 30 min with varying concentrations of leukotriene B4 or 
leukotriene D4 and ATPase activity was then measured at 
pH 7.4. The data-points show mean ± s.e. from three inde-
pendent assays in each of which SCH28080-sensitive ATPase 
activity was measured in triplicate.
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ML 3000 inhibits acid accumulation in rabbit gastric parietal  cells Figure 7
ML 3000 inhibits acid accumulation in rabbit gastric 
parietal cells. (A) Dose-dependent inhibition by ML 3000 
of histamine-stimulated (100 µM) acid accumulation by rabbit 
gastric parietal cells (IC50 = 40 µM). (B) Dose-dependent 
inhibition by ML 3000 of forskolin-stimulated (100 µM) acid 
accumulation by rabbit gastric parietal cells (IC50 = 45 µM). 
The data-points show mean ± s.e. from four independent 
assays in each of which acid accumulation into parietal cells 
was measured in duplicate.
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although the latter effect appears unrelated to the 5-lipox-
ygenase inhibitory activity of ML 3000 (Figure 8D).
Published IC50 for omeprazole with respect to gastric pro-
ton pump activity range from 470 nM to 36 µM
depending on the conditions of the assay [23-25]. For
other PPIs, picoprazole IC50 is 2 µM [26], rabeprazole IC50
is 72 nM [23], and lansoprazole IC50 is 2.1 µM [27]. The
wide range of published PPI IC50 values for microsomal
H,K-ATPase reflects the mechanistic necessity for
compound acidification to allow formation of a thiol-
reactive sulfoxide intermediate which then irreversibly
Effects of ML 3000 on IL-1β-induced IL-8 secretion in human gastric adenocarcinoma (AGS) cells Figure 8
Effects of ML 3000 on IL-1β-induced IL-8 secretion in human gastric adenocarcinoma (AGS) cells. ML 3000 inhib-
ited both baseline (A) and IL-1β-stimulated (B) IL-8 secretion, with IC50s of 0.46 µM (CI = 0.09 – 2.4 µM) and 1.1 µM (CI = 
0.52 – 2.2 µM) respectively. The 5-lipoxygenase-specific inhibitor ZD-2138 showed dose-dependent inhibition of baseline AGS 
cell IL-8 secretion (C), with an IC50 of 58 nM (CI = 15.6 – 218 nM) and minimal effect on AGS cell IL-1β-stimulated IL-8 secre-
tion (D). The data-points show mean ± s.e. from three independent assays in each of which IL-8 concentrations were meas-
ured in triplicate.
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derivatizes H,K-ATPase α subunit cysteine residues lead-
ing to enzyme inhibition.
These ML 3000 data also contrast dramatically with ome-
prazole inhibition of acid accumulation in isolated pari-
etal cells. Acid secretory capacity IC50s (in isolated parietal
cells) of proton pump inhibitors (PPIs) such as
omeprazole, rabeprazole, and lansoprazole are in the
range 59 nM to 360 nM [27,28]. The greater potency of
PPIs in the context of acid secretory capacity compared to
microsomal H,K-ATPase (IC50s ranging from 72 nM to 40
µM) reflects more complete acid activation of PPIs in iso-
lated parietal cell canaliculi than occurs in in vitro micro-
somal assays at pH 6.1 or higher.
The PGE2 data are in contrast to a previous study in which
no inhibitory effect of PGE2 on pig gastric H,K-ATPase
[29] was reported. Differences in the specific ATPase assay
used in that study may account for this discrepancy. Since
ML3000 and arachidonic acid are anionic amphiphiles,
their inhibitory effects could result from specific interac-
tions with H,K-ATPase subunit binding sites, or from less-
specific hydrophobic interactions with H,K-ATPase-asso-
ciated microsomal membrane lipids, or a combination of
both factors.
The reversibility of ML 3000 inhibition of H,K-ATPase
activity in vitro, shown in Figure 2B, contrasts with the
irreversibility of H,K-ATPase inhibition by substituted
benzimidazoles such as omeprazole or lansoprazole. In a
pharmacological context, relief of acid secretory inhibi-
tion by the latter reagents is dependent primarily on de
novo synthesis and apical membrane targeting of H,K-
ATPase subunits, and to some extent on reduction of the
inhibitory disulfide bond by intracellular glutathione.
Reversible inhibition of H,K-ATPase by ML 3000 offers
the potential for less profound inhibition of acid secre-
tion, thereby attenuating rebound acid hypersecretion
which has been reported in H. pylori-negative subjects
after omeprazole treatment [30]. At the same time, the
potentially less-prolonged acid inhibition by ML 3000
may be insufficient to prevent NSAID-ulcers in humans.
In vitro reversibility of ML 3000 inhibition of H,K-ATPase
activity is also significant in a mechanistic sense, since it
allows further analysis of ML 3000 inhibition using classi-
cal Michaelis-Menten kinetic assays to determine whether
inhibition is competitive, non-competitive, or mixed,
each of which options present differing lines of further
investigation with respect to pharmaceutical applications
of ML 3000.
To the extent that IL-8 is a potent inflammatory mediator
in the gastric mucosa, our preliminary finding that ML
3000 profoundly inhibits baseline and IL-1β-stimulated
IL-8 secretion in gastric epithelial cells is consistent with
the previously-observed gastric sparing properties of ML
3000. The sensitivity of baseline IL-8 secretion to ZD-
2138 indicates that ML 3000 inhibition may be mediated
by ML 3000 5-lipoxygenase inhibitory activity. In con-
trast, the relative insensitivity of IL-1β-stimulated IL-8
secretion to ZD-2138 suggests that ML 3000 inhibition is
not mediated by ML 3000 5-lipoxygenase inhibitory activ-
ity. ML 3000 cycloxygenase inhibitory activity or other as
yet undetected activity may underlie the inhibition of IL-
1β-stimulated IL-8 secretion in this model. Important
objectives of further studies of ML 3000 are definition of
the mechanisms of H,K-ATPase inhibition and AGS cell
IL-8 secretory inhibition, an assessment of ML 3000 in vivo
acid inhibitory efficacy in a rat model, and whole body
distribution and localization of the compound.
Conclusions
This study provides evidence that the pyrrolizine deriva-
tive ML 3000 inhibits gastric H,K-ATPase activity and gas-
tric epithelial cell IL-8 secretion. The data indicate that the
anti-secretory properties of ML 3000, in terms of both acid
and IL-8 secretion, may underlie previously-noted gastric-
sparing properties of the drug. The apparent mechanistic
differences between ML 3000 and omeprazole inhibition
of H,K-ATPase identify ML 3000-based compounds as a
potentially important novel class of proton pump
inhibitors.
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